Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program

Pierluigi Zinzani, C. Pellegrini, Giuseppe Cerciello, Federico Monaco, Stefano Volpetti, Annalisa Peli, Emanuele Angelucci, Paolo Corradini, Maria Cristina Cox, Attilio Guarini, Maurizio Musso, Paola Bresciani, Gabriella Amato, Atto Billio, Giuseppe Caparrotti, Amalia Figuera, L. Nassi, Francesco Gaudio, Alberto Grossi, Francesco OnidaMichele Merli, Luigi Rigacci, Lisa Argnani

Research output: Contribution to journalArticlepeer-review

Abstract

Clinical trial results indicate that romidepsin, a histone deacetylase inhibitor, is a promising treatment in relapsed/refractory T-cell lymphomas (TCLs). This retrospective multicenter study was conducted in patients with relapsed/refractory TCL treated with romidepsin monotherapy through a Named Patient Program (NPP) in Italy. Principal endpoints were overall response rate (ORR), safety, and overall survival (OS). The ORR in 33 evaluable patients was 24.2% with an ORR in the cutaneous TCL of 35.7%. Global OS was 39.3% at 30 months. There were not any specific differences on hematological and extrahematological adverse events. Data from patients treated with romidepsin outside a controlled clinical trial give additional information about the clinical use, efficacy, and toxicity of the drug given to relapsed or refractory TCL patients in a real life context as TCLs are rare diseases and more information is needed. These findings suggest that romidepsin is effective and safe for heavily pretreated TCL patients.

Original languageEnglish
Pages (from-to)2370-2374
Number of pages5
JournalLeukemia and Lymphoma
Volume57
Issue number10
DOIs
Publication statusPublished - 2016

Keywords

  • Real life
  • refractory
  • relapsed
  • romidepsin
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program'. Together they form a unique fingerprint.

Cite this